Home
Long-term effect of aspirin on colorectal cancer incidence and mortality: 20-year follow-up of five randomised trials - Lancet. 2010 Nov 20;376(9754):1713-4.
BACKGROUND: High-dose aspirin (≥500 mg daily) reduces long-term incidence of colorectal cancer, but adverse effects might limit its potential for long-term prevention. The long-term effectiveness of lower doses (75-300 mg daily) is unknown. We assessed the effects of aspirin on incidence and mortality due to colorectal cancer in relation to dose, duration of treatment, and site of tumour.
RESULTS: In the four trials of aspirin versus control (mean duration of scheduled treatment 6·0 years), 391 (2·8%) of 14 033 patients had colorectal cancer during a median follow-up of 18·3 years. Allocation to aspirin reduced the 20-year risk of colon cancer (incidence hazard ratio [HR] 0·76, 0·60-0·96, p=0·02; mortality HR 0·65, 0·48-0·88, p=0·005), but not rectal cancer (0·90, 0·63-1·30, p=0·58; 0·80, 0·50-1·28, p=0·35). Where subsite data were available, aspirin reduced risk of cancer of the proximal colon (0·45, 0·28-0·74, p=0·001; 0·34, 0·18-0·66, p=0·001), but not the distal colon (1·10, 0·73-1·64, p=0·66; 1·21, 0·66-2·24, p=0·54; for incidence difference p=0·04, for mortality difference p=0·01).
However, benefit increased with scheduled duration of treatment, such that allocation to aspirin of 5 years or longer reduced risk of proximal colon cancer by about 70% (0·35, 0·20-0·63; 0·24, 0·11-0·52; both p<0·0001) and also reduced risk of rectal cancer (0·58, 0·36-0·92, p=0·02; 0·47, 0·26-0·87, p=0·01). There was no increase in benefit at doses of aspirin greater than 75 mg daily, with an absolute reduction of 1·76% (0·61-2·91; p=0·001) in 20-year risk of any fatal colorectal cancer after 5-years scheduled treatment with 75-300 mg daily. However, risk of fatal colorectal cancer was higher on 30 mg versus 283 mg daily on long-term follow-up of the Dutch TIA trial (odds ratio 2·02, 0·70-6·05, p=0·15).
INTERPRETATION: Aspirin taken for several years at doses of at least 75 mg daily reduced long-term incidence and mortality due to colorectal cancer. Benefit was greatest for cancers of the proximal colon, which are not otherwise prevented effectively by screening with sigmoidoscopy or colonoscopy. For more details check PubMed page
The event organised by the project team in order to promote the results of the project "GRID Resources Centre for Translational Research in Oncology / OncoNET RO" with the purpose of discussing the potential developments in medicine using GRID/HPC technology will be held on December 3rd, 12:00, into the Council Hall of the Faculty of Medicine. For details and agenda check the Events page.
The Romanian Educational Network (RoEduNet) has organized its 9-th International Conference in Sibiu, Romania, on "Lucian Blaga" University. The purpose of the conference is to bring together academics and researchers working in the dynamical domain of computer networking, in its technical, social and strategic aspects, with a special focus on directions and applications in education and research. One of the important topics was HPC/GRID Computing and IPv6. Details on Conference site
The European Commission initiate a project related with of IPv6 Deployment Monitoring. This project runs for two years, and started in January 2009. A consortium of TNO and GNKS is doing the IPv6 deployment research through metrics analyses, questionnaires and live traffic measurements in order to determine the number of IPv6 enabled users in Europe in the period 2009—2010. The project IPv6 Deployment Monitoring has four main objectives:
- Further developing the proposed user oriented methodology in order to determine the number of IPv6 enabled users.
- Conducting two specific IPv6 measurement campaigns for Europe in 2009 and 2010.
- Assessing the global deployment, quality and security of current IPv6 products and services by studying available statistics, performing additional surveys and interviewing companies and worldwide experts.
- Disseminating the results in such a way that the EU can use them directly for further policy and actions